



# XVII INTERNATIONAL AIDS CONFERENCE

3-8 August 2008 | Mexico City

## Poster Exhibition

### Track A - Resistance in Treatment-experienced Patients

**WEPE0034 - Drug resistance degree is associated with duration of ARV exposure and predicted by baseline CD4 and gender in HIV-infected patients failing first-line WHO-recommended ARV regimen: a cross-sectional viral load survey of a cohort in Cameroon (Médecins sans Frontières-Ministry of Health)**

A. Soria<sup>1</sup>, K. Porten<sup>2</sup>, J.-C. Fampou Toundji<sup>3</sup>, R. Mougoutou<sup>3</sup>, J. Kfutwah Anfumbom<sup>4</sup>, D. Rousset<sup>4</sup>, R. Teck<sup>3</sup>, L. Ciaffi<sup>5</sup>, L. Galli<sup>1</sup>, A. Calmy<sup>5</sup>, A. Lazzarin<sup>1</sup>, N. Gianotti<sup>1</sup>

<sup>1</sup>San Raffaele Scientific Institute, Infectious Diseases, Milan, Italy, <sup>2</sup>Epicentre, Geneva, Switzerland, <sup>3</sup>Médecins sans Frontières, Yaoundé, Cameroon, <sup>4</sup>Centre Pasteur du Cameroun, Yaoundé, Cameroon, <sup>5</sup>Médecins sans Frontières, Geneva, Switzerland

**Background:** The absence of routine virologic monitoring in resource-limited settings may favor accumulation of resistance mutations, thus hampering second-line treatment efficacy. Knowing predicting factors for resistance extent could help to preserve options for future salvage regimens.

**Methods:** Cross-sectional viral load (VL) sampling with genotyping for VL >400 copies/mL on cameroonian HIV-infected subjects receiving ARV (nevirapine/efavirenz, stavudine/zidovudine, lamivudine) since 2001.

**Results:** Among 573 subjects with sampled VL, 97 (16.9%) had detectable viremia, 84 were genotyped (70% women). The mean number of reverse-transcriptase (RT) and, specifically, NRTI mutations increased per year of ARV exposure (0.33, 1.74, 2.81, 2.77 and 0.17, 0.85, 1.27, 1.77 at 1, 2, 3, >3 years; p for trend 0.03 and 0.02, respectively). Baseline CD4 counts were correlated with number of RT, NRTI and NNRTI mutations ( $r=-0.35$ ,  $-0.38$ ,  $-0.23$ ;  $p=0.0009$ ,  $0.0003$ ,  $0.04$ , respectively). Multivariable analysis: by GLM (covariates: age, baseline BMI, baseline CD4 $\leq$  or  $>50/mm^3$ , gender, WHO stage), the adjusted mean number of RT, NRTI and NNRTI mutations was higher for subjects with baseline CD4 $\leq 50/mm^3$  vs  $>50/mm^3$  (3.75 vs 1.32, 2.10 vs 0.56, 1.65 vs 0.76;  $p<0.0001$ ,  $<0.0001$ ,  $0.005$ , respectively); the adjusted mean number of RT and NNRTI mutations in women vs men was 3.16 vs 1.91,  $p=0.03$  and 1.60 vs 0.81,  $p=0.015$ , respectively. At logistic regression, being a woman was predictive of  $\geq 1$  NRTI mutation (OR 4.05, 95%CI 1.19-16.67); baseline CD4 $\leq 50/mm^3$  was predictive of  $\geq 1$  RT mutation (OR 5.36, 95%CI 1.68-20.58),  $\geq 1$  NRTI mutation (OR 7.49, 95%CI 2.20-32.14),  $\geq 1$  NNRTI mutation (OR 4.25, 95%CI 1.36-15.48),  $\geq 1$  TAM (OR 8.45, 95%CI 2.16-40.16), and etravirine resistance (OR 4.72, 95%CI 1.53-15.70).

**Conclusions:** Failing patients with baseline CD4  $\leq 50/mm^3$  are at higher risk of extensive drug-resistance, that increases over time of ARV exposure when virologic monitoring is not available. Earlier ARV initiation, and targeted VL testing, should be considered to preserve options for second-line regimens in resource-limited settings.

Presenting author email: [soria.alessandro@hsr.it](mailto:soria.alessandro@hsr.it)